Drug Information

Drug General Information
Drug ID
D0L3RO
Former ID
DIB012699
Drug Name
TAS-119
Indication Late-stage solid tumors [ICD9: 140-199, 210-229; ICD10:C00-C75, C7A, C7B, D10-D36, D3A] Phase 1 [549555]
Company
Taiho oncology
Target and Pathway
Target(s) Aurora kinase A Target Info Inhibitor [549967]
KEGG Pathway Oocyte meiosis
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M Transition
WikiPathways EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 549555Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040598)
Ref 549967TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.